Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q3 2020 Results - Earnings Call Transcript

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q3 2020 Earnings Conference Call November 5, 2020 9:00 AM ET

Company Participants

Kristen Sheppard - Senior Vice President of Investor Relations
John Butler - President and Chief Executive Officer
Dave Spellman - Chief Financial Officer

Conference Call Participants

Ally Bratzel - Piper Sandler
Alex Bouilloux - Mizuho
Thomas Yip - H.C. Wainwright
Bert Hazlett - BTIG
Gil Blum - Needham & Company
Victor Ma - RBC Capital Markets

Operator

Good morning, ladies and gentlemen, and welcome to the Akebia Therapeutics' Third Quarter Financial Results and Business Update Conference Call. As a reminder, this call is being recorded.

I would now like to introduce your host for today's event, Kristen Sheppard, Senior Vice President of Investor Relations.

Kristen Sheppard

Thank you and welcome to Akebia's third quarter fiscal 2020 financial results and business update conference call. My name is Kristen Sheppard, Senior Vice President of Investor Relations at Akebia. Thank you so much for joining us to discuss Akebia's Top-line data for INNO2VATE, our global Phase III program of our product candidate, vadadustat, for the treatment of anemia due to chronic kidney disease in adult dialysis-dependent patients.

Please note that the press release detailing our results to the third quarter was issued earlier this morning and is available on our Investor Relations website. For your convenience, a replay of today's call will also be available on our website shortly after we conclude today's call. Joining me for today's call is John Butler, our Chief Executive Officer and David Spellman, our Chief Financial Officer.

Before we begin, I'd like to remind everyone that this call includes forward-looking statements. Each forward-looking statements contained in this call is subject to risks and uncertainties that could cause actual results to differ materially from those described in these statements. Additional information regarding these factors